Latest Hospitality News

Alcidion Group Limited has upgraded its full-year EBITDA guidance for FY25, now expecting earnings to exceed $4.5 million, driven by contract expansions, cost discipline, and favorable currency effects.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.

Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.

Radiopharm Theranostics has initiated dosing in its Phase 1 HEAT trial of 177Lu-RAD202, a novel radiotherapeutic aimed at advanced HER2-positive solid tumors, marking a key step in its clinical development.

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

ReNerve Limited has entered a strategic partnership with Berkeley Biologics to develop and commercialise two new tissue-based product ranges, aiming to expand its footprint in the US surgical market by the end of 2025.

Austco Healthcare has completed its strategic acquisition of New Zealand’s G&S Technologies, enhancing its healthcare communication offerings and direct sales reach in the region.

Beamtree Holdings has forged a strategic alliance with the NHS Confederation to launch a pioneering healthcare analytics platform across UK NHS Trusts, marking a significant step in its international expansion.